Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04531475
Other study ID # SND-X842-201
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 22, 2019
Est. completion date December 31, 2020

Study information

Verified date August 2020
Source Jiangsu Sinorda Biomedicine Co., Ltd
Contact Ming Lu
Phone +8618684676235
Email lum@sinorda.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.


Description:

It is designed as a multicenter, randomized, double-blind, double-simulation, high and low dose group, active comparator-controlled, parallel-group study to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date December 31, 2020
Est. primary completion date October 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Males or females, 18 years = age = 75 years;

2. Within 14 days prior to randomization, the subjects are endoscopically diagnosed with reflux esophagitis from Los Angeles (LA) grade A to D (notes: the percent of the subjects with LA grade A of RE should be no more than 60% of the all subjects who are planned to be enrolled in the study);

3. Subjects fully understand the trial contents, participate in the trial voluntarily, and sign the informed consent forms.

Exclusion criteria:

1. Subjects who receive X842 capsules or other P-CAB drugs in previous clinical studies;

2. Subjects known to be allergic to X842 capsules or lansoprazole enteric-coated capsules, or relevant excipients of X842 capsules or lansoprazole enteric-coated capsules, such as lactose, microcrystalline cellulose, croscarmellose sodium, sodium dodecyl sulfate, sodium stearyl fumarate, and silicon dioxide;

3. Subjects unable to receive upper gastrointestinal endoscopy;

4. Subjects unable to independently complete the subject diary cards;

5. Subjects known to have any concomitant disease that may affect the esophagus (eosinophilic esophagitis, esophageal varices, dermatosclerosis, viral or fungal infectious esophagitis, or esophageal stenosis), or have a history of esophageal radiotherapy or cryotherapy (but subjects are eligible for this study if they have concomitant esophageal hiatal hernia)

6. Subjects known to have a history of Barrett's esophagus, or who have Barrett's esophagus discovered during endoscopy at screening;

7. Subjects who have acute upper gastrointestinal hemorrhage within 4 weeks prior to enrollment;

8. Subjects with active peptic ulcer discovered during upper gastrointestinal endoscopy, or subjects with suspicious or definite malignancies;

9. Subjects known to have Zollinger-Ellison syndrome or inflammatory bowel disease (IBD);

10. Subjects with concomitant cholecystolithiasis, gallbladder wall crystal or gallbladder polyp discovered by B ultrasonography at screening;

11. Subjects with a history of surgery that may affect the esophagus (for example, fundoplication and mechanical distension for esophageal stenosis), or subjects with a history of cholecystectmy or surgery of stomach or duodenum (except endoscopic excision of benign polyps, and except simple suture surgeries such as for gastric perforation);

12. Subjects with a history of malignancies within 5 years prior to screening (a subject can participate in the study if his /her skin basal cell carcinoma or carcinoma in situ of uterine cervix has been cured);

13. Subjects with concomitant serious diseases of central nervous system, cardiovascular system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system, or hematological system, and the investigator thinks these diseases may mix the study results up or affect the safety of the subject;

14. Laboratory test results at screening showing that ALT or AST is larger than 1.5 times of the upper limit of normal, or kidney function index Cr is larger than the upper limit of normal (a re-examination is permitted in the study, and subjects will be excluded if they still fail to meet the inclusion criteria);

15. Subjects who use proton pump inhibitors (PPIs), P-CABs, histamine2 receptor antagonists (H2RAs), or gastric mucosal protectors (except hydrotalcite) within 2 weeks prior to randomization;

16. Subjects who chronically use (>12 doses / month) non-steroidal anti-inflammatory drug (including cyclooxygenase-2 inhibitor), anti-platelet drug (such as aspirin and clopidogrel), or anticoagulant (such as Warfarin) prior to randomization, and can not stop the medication during the trial;

17. At screening, subjects with clinically significant ECG abnormalities, including serious arrhythmia, multifocal preventricular contraction (PVC), grade II or above atrioventricular block, and prolongation of the Q-T interval (QTc=450 ms in males and QTc=470 ms in females);

18. Diabetic subjects with poorly controlled blood glucose level (fasting blood glucose (FBG) > 10.0 mmol/L), or hypertensive subjects with poorly controlled blood pressure (systolic pressure =150 mmHg or diastolic pressure =100 mmHg);

19. Subjects with known acquired immunodeficiency syndrome (AIDS);

20. Subjects who are using atazanavir sulfate or ripivirin hydrochloride at screening;

21. Subjects with a history of long-term abuse of drug or alcohol within 6 months prior to screening;

22. Female subjects with suspicious or known pregnancy, those in breast-feeding period, or those who are planned to become pregnant during the trial. At the investigator's discretion, women of childbearing age who cannot use a medically-proven and reliable method of contraception from signing the informed consent forms to 4 weeks after the last dose of the study;

23. Subject who plan to have a surgery requiring hospitalization, or subject who need to have a surgery during his/her participation in the study;

24. Subjects who participate in other drug/medical device clinical studies and use the drug/medical device within 3 months prior to randomization;

25. Subjects who are considered unsuitable for participating in this trial by investigators.

Study Design


Intervention

Drug:
X842
X842 capsules
X842 Placebo
X842 placebo-matching capsules
Lansoprazole
Lansoprazole capsules
Lansoprazole Placebo
Lansoprazole placebo-matching capsules

Locations

Country Name City State
China Beijing Friendship Hospital, Capital Medical University Beijing Beijing
China Beijing Luhe Hospital Capital Medical University Beijing Beijing
China The First Affiliated Hospital of Bengbu Medical College Bengbu Anhui
China Binzhou Medical University Hospital Binzhou Shandong
China Xiangya Hospital Central South University Changsha Hunan
China The First people's Hospital of Changzhou Changzhou Jiangsu
China Affiliated Hospital of Xiangnan University Chenzhou Hunan
China The Second Affiliated Hospital of Chongqi Medical University Chongqing Sichuan
China The Affiliated Hospital of Guzihou Medical University Guiyang Guizhou
China Jinan Central Hospital Jinan Shandong
China Liuan People's Hospital Liu'an Anhui
China Nanjing First Hospital Nanjing Jiangsu
China Jiangxi PingXiang People's Hospital Pingxiang Jiangxi
China Tongji Hospital of Tongji University Shanghai Shanghai
China Taizhou Municipal Hospital Taizhou Zhejiang
China Affiliated Hospital of Zunyi Medical University Zunyi Guizhou

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Sinorda Biomedicine Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Subjects Whose Reflux Esophagitis is Cured as Confirmed by Endoscopy at Week 4 of Treatment Subjects cured of RE are defined as subjects who are endoscopically confirmed to be cured of RE. 4 weeks
Secondary Proportion of Subjects Whose Reflux Esophagitis LA Grade is Decreased by =1 as Confirmed by Endoscopy at Week 4 of Treatment The endoscopic results must describe RE severity according to the LA grading criteria. 4 weeks
Secondary Changes in Gerd-Q Score at Week 2 and 4 Compared With the Baseline Subjects must record RE symptoms that occur within 7d prior to each visit in the Gerd-Q under the guidance of the investigator. Week 2 and Week 4
Secondary Changes in Serum Gastrin at Week 2 and 4 of Treatment Compared with the Baseline Serum gastrin testing will be conducted at the central laboratory. The change between the serum gastrin values collected at Weeks 2 and 4 relative to baseline. Week 2 and Week 4
Secondary Measurement of the PK Profile Plasma concentrations of X842 and its metabolites are measured to determine X842 exposure in patients. Week 2 and Week 4
Secondary Number of Subjects Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE) Adverse event is defined as any adverse medical event that is observed in a subject who is receiving a drug treatment or in a clinical study, and that does not necessarily have a causal relationship with the treatment. Up to 6 weeks
Secondary Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of blood serum Number of subjects with any markedly abnormal values in laboratory tests of blood serum collected throughout study is reported. Up to 6 weeks
Secondary Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of blood Number of subjects with any markedly abnormal values in laboratory tests of blood collected throughout study is reported. Up to 6 weeks
Secondary Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of urine Number of subjects with any markedly abnormal values in laboratory tests of urine collected throughout study is reported.collected throughout study is reported. Up to 6 weeks
Secondary Number of Subjects With Markedly Abnormal Electrocardiogram (ECG) Findings The investigator or the sub-investigator interpreted the ECG using one of the following categories: "within normal limits", "abnormal but not clinically significant", or "abnormal and clinically significant". Up to 6 weeks
Secondary Vital signs of body temperature °C = degrees Celsius Up to 6 weeks
Secondary Vital signs of blood pressure Blood pressure measurements included systolic (mmHg) and diastolic (mmHg). Up to 6 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06170060 - Treatment of Reflux With Sleeve Gastrectomy N/A
Not yet recruiting NCT06062225 - Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy N/A
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Not yet recruiting NCT06056973 - Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis Phase 4
Completed NCT01008696 - An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Phase 4
Recruiting NCT05899491 - Role of ARMA in Selective Subset of Refractory GERD Patients. N/A
Recruiting NCT01311908 - Incidence of Reflux Esophagitis After Pancreaticoduodenectomy N/A
Completed NCT03214081 - Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
Not yet recruiting NCT01560598 - Adipokines and the Risk of Reflux Esophagitis N/A
Completed NCT00859287 - Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis N/A
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Recruiting NCT04657848 - Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy N/A
Completed NCT02477475 - Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes N/A
Completed NCT03553563 - A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Phase 3
Completed NCT01381991 - The Efficacy of i-Scan for Detecting Reflux Esophagitis N/A
Completed NCT04673643 - Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Reflux Esophagitis N/A
Completed NCT00634114 - Reflux Esophagitis Phase III Study (Maintenance Treatment) Phase 3
Completed NCT00586963 - Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis N/A
Completed NCT03388047 - Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus N/A
Recruiting NCT00155805 - Immunologic Factors in Reflux Esophagitis and Barrett’s Esophagus N/A